\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ surgery\\ and\\ radiation\\ therapy\\.\\ \\ no\\ recurrence\\ at\\ 1\\ year\ \(0\)\
\-\ \\â\\€\\¢\\ a\\ 1\\.5\\ cm\\ mass\\ lying\\ behind\\ cauda\\ equina\\ at\\ l1\\-2\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ mass\\ enhances\\ following\\ contrast\\ administration\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ no\\ associated\\ bone\\ changes\\ nor\\ neuroforaminal\\ enlargement\\.\ \(0\)\
\-\ ependymoma\\.\\ grade\\ ii\ \(0\)\
\-\ \\â\\€\\¢\\ ependymoma\\ \\(myxopapillary\\)\ \(0\)\
\-\ \\â\\€\\¢\\ herniated\\ disc\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ schwannoma\ \(0\)\
\-\ \\â\\€\\¢\\ meningioma\ \(7\)\
\-\ \\â\\€\\¢\\ paraganglioma\ \(0\)\
\-\ 57\\ year\\ old\\ man\\ with\\ back\\ and\\ right\\ leg\\ pain\\ for\\ 2\\ months\\.\ \(1\)\
\-\ prior\\ to\\ visiting\\ our\\ facility\\,\\ an\\ mri\\ at\\ an\\ outside\\ hospital\\ revealed\\ a\\ mass\\ at\\ l1\\-2\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.15329488222133686\ \(0\)\
\-\ l1\\-2\\:\\ 0\\.14933931032415618\ \(0\)\
\-\ neuroforaminal\\:\\ 0\\.08387941451411292\ \(0\)\
\-\ ependymoma\\:\\ 0\\.08315403993886439\ \(0\)\
\-\ visiting\\:\\ 0\\.07832696208187388\ \(0\)\
\-\ myxopapillary\\:\\ 0\\.07193797659380737\ \(0\)\
\-\ cauda\\:\\ 0\\.06222256489791502\ \(0\)\
\-\ equina\\:\\ 0\\.06222256489791502\ \(0\)\
\-\ paraganglioma\\:\\ 0\\.057490846732068876\ \(0\)\
\-\ herniated\\:\\ 0\\.053083617296110566\ \(0\)\
\-\ lying\\:\\ 0\\.05226288302971768\ \(0\)\
\-\ facility\\:\\ 0\\.05078677932146702\ \(0\)\
\-\ 57\\:\\ 0\\.050615601528335066\ \(0\)\
\-\ at\\:\\ 0\\.050337528383984045\ \(0\)\
\-\ nor\\:\\ 0\\.04964155632518629\ \(0\)\
\-\ behind\\:\\ 0\\.049037536203938345\ \(0\)\
\-\ 1\\.5\\:\\ 0\\.046437213496701026\ \(0\)\
\-\ our\\:\\ 0\\.04415139383543624\ \(0\)\
\-\ enhances\\:\\ 0\\.04387385794407574\ \(0\)\
\-\ disc\\:\\ 0\\.04325257083711979\ \(0\)\
\-\ schwannoma\\:\\ 0\\.04242242976337442\ \(0\)\
\-\ recurrence\\:\\ 0\\.040520892268849064\ \(0\)\
\-\ ii\\:\\ 0\\.04006108379395027\ \(0\)\
\-\ outside\\:\\ 0\\.038960976164259906\ \(0\)\
\-\ mass\\:\\ 0\\.03875416327002928\ \(0\)\
\-\ administration\\:\\ 0\\.03856152461851272\ \(0\)\
\-\ enlargement\\:\\ 0\\.03685400441831625\ \(0\)\
\-\ leg\\:\\ 0\\.03652388378922605\ \(0\)\
\-\ meningioma\\:\\ 0\\.03571836235277255\ \(0\)\
\-\ grade\\:\\ 0\\.03537866079294533\ \(0\)\
\-\ hospital\\:\\ 0\\.034968439836610035\ \(0\)\
\-\ non\\-contributory\\:\\ 0\\.03430474139355301\ \(0\)\
\-\ back\\:\\ 0\\.030642025384211707\ \(0\)\
\-\ radiation\\:\\ 0\\.030480991843068874\ \(0\)\
\-\ revealed\\:\\ 0\\.029809498802892315\ \(0\)\
\-\ changes\\:\\ 0\\.02662008669820718\ \(0\)\
\-\ following\\:\\ 0\\.026361714748925524\ \(0\)\
\-\ an\\:\\ 0\\.02568836661488543\ \(0\)\
\-\ months\\:\\ 0\\.025368927116196382\ \(0\)\
\-\ cm\\:\\ 0\\.024912566498010713\ \(0\)\
\-\ therapy\\:\\ 0\\.02483305213305014\ \(0\)\
\-\ prior\\:\\ 0\\.02384905187176482\ \(0\)\
\-\ metastatic\\:\\ 0\\.023381623952348808\ \(0\)\
\-\ bone\\:\\ 0\\.023080811754998584\ \(0\)\
\-\ surgery\\:\\ 0\\.022554337656089943\ \(0\)\
\-\ 1\\:\\ 0\\.02210137356477942\ \(0\)\
\-\ man\\:\\ 0\\.021966650468369556\ \(0\)\
\-\ associated\\:\\ 0\\.021918071325083714\ \(0\)\
\-\ mri\\:\\ 0\\.02133995494472413\ \(0\)\
\-\ contrast\\:\\ 0\\.02079104007399897\ \(0\)\
\-\ year\\:\\ 0\\.02078489715810684\ \(0\)\
\-\ 2\\:\\ 0\\.02000113583163637\ \(0\)\
\-\ no\\:\\ 0\\.018705307623995696\ \(0\)\
\-\ disease\\:\\ 0\\.015181929795822871\ \(0\)\
\-\ pain\\:\\ 0\\.011343567038377552\ \(0\)\
\-\ right\\:\\ 0\\.009800344664243659\ \(0\)\
\-\ old\\:\\ 0\\.009510158661546246\ \(0\)\
\-\ a\\:\\ 0\\.008621734822143505\ \(0\)\
\-\ for\\:\\ 0\\.007925088572203426\ \(0\)\
\-\ \\(\\:\\ 0\\.007851757893955005\ \(0\)\
\-\ \\)\\:\\ 0\\.007755844479492446\ \(0\)\
\-\ to\\:\\ 0\\.004642044656988981\ \(0\)\
\-\ and\\:\\ 0\\.003913239255048227\ \(0\)\
\-\ \\,\\:\\ 0\\.002942500712144428\ \(0\)\
\-\ \\.\\:\\ 0\\.002701051659580695\ \(0\)\
\-\ with\\:\\ 0\\.0012717845227161928\ \(0\)\
